as low as 40 nM, signifi cantly enhances rAAV-mediated (both singleand double-stranded) and rAdv-mediated transgene expression in different cell lines. Furthermore, combination therapies of bufalin and rAdv-p53 strongly inhibited the proliferation of different malignant cell lines, including human cervical cancer and HCC cells. The therapeutic effect was more effi cient than either treatment alone, and in a time-and dose-dependent manner. It was evident that the percentage of cells undergone apoptosis increased signifi cantly after treatment. These studies suggested a potential combinatorial therapy of bufalin and bufalin-containing medicine in future malignant celltargeted, viral vector-based gene therapy.
1 Surgery, Univerisity of Chicago, Chicago, IL.
The dismal clinical context of advanced-grade glioma warrants the development of novel strategies with the potential for direct patient impact. In this regard, conditionally replicating adenoviruses (CRAds) represent a potentially effective, novel approach for glioma therapy Furthermore, the CRAd-loaded tumor-tropic stem cell carrier approach has shown appreciable preclinical effi cacy. However, several improvements can be achieved in regards to the critical functions of CRAds: more effi cient targeting, directed tumor-specifi c replication, and restricted lateral spread of glioma.
The development of an adenoviral vector capable of targeting, being initially "loaded on a cell carrier," and "specifi cally targeted to glioma", respectively, represents a critical fi eld challenge to allow for the development of tumor targeted therapies for treating gliomas. The initiation point for demonstrating this novel approach is the development of specifi cally targeted adenovirus fi bers, which dictate the attachment of an adenoviral vector to a target cell. For this, we have generated a set of a specifi c cell targeting fi bers through the incorporation of phage panned peptides specifi c for glioma cells and for cells expressing CD133, a marker for stem cell carriers, on a Fiber Fibritin-based Ad5 fi ber, designated as MGFF and CD133FF. Then, we generated Ad5MGFF-CMV-GFP (and Survivin-E1) and HEK293 stably expressing CD133FF.
Ad5MGFF infects glioma cell lines with high specifi city, exhibiting drastically lower infectivity in non-cancer cell lines (including stem cell carrier cell lines) and other types of tumor cell lines. To load this glioma specifi c Ad5MGFF, we propagated this virus in HEK293 stably expressing CD133FF, generating pseudo-typed CD133FF expressing Ad5. The CD133FF fi ber pseudo-typed Ad5MGFF Janus virus was effi ciently loaded on a neural stem cell carrier, replicated inside the cell carrier, and was released as highly glioma-specifi c Ad5MGFF. We will show corroborating data regarding effi cient serial targeting-cell carrier and glioma cell, glioma-specifi c replication, and restricted lateral spread of glioma.
By maximizing advantages of cell carrier based therapy through effi cient natural cell tropism and protection from immune surveillance, this novel Janus viral vector generation technique we describe herein has markedly profound potential as a cell carrier-based cancer therapy with systemic administration of adenoviral vector for many different types of cancer therapy.
Biodistribution of Oncolytic Adenovirus After the Injection of Carrier Cells Infected With Oncolytic Adenovirus
Katsuyuki Hamada, 1 Kazuko Takagi, 1 Wenlin Huang, 2 Hiroshi Itoh, 3 Kenzabro Tani, 4 Akihiro Nawa. 1 1 Obstetrics and Gynecology, Ehime University, Toon, Ehime, Japan; 2 Cancer Center, Su Yat-sen University, Guangzhou, Guangdong, China; 3 Animal Medical Center, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan; 4 Advanced Molecular and Cell Therapy, Kyusyu University, Fukuoka, Japan. Although replication-competent viruses have been developed to treat cancers, their cytotoxic effects are insuffi cient, since infection with them is inhibited by generation of neutralizing antibodies. To address this limitation, we developed a carrier cell system to deliver a replication-competent adenovirus. Carrier cells infected with oncolytic adenovirus were injected into syngeneic subcutaneous ovarian tumors after immunization with adenovirus and induced complete tumor regression by the induction of antiadenoviral and antitumoral CTL responses. To start clinical trial, toxicity and biodistribution study were carried out in nude mice, rabbits and beagle dogs. Acute toxicity and distribution test were carried out after the single injection of carrier cells into ovarian tumor in nude mice. Chronic toxicity test was carried out by 8 injections of carrier cells into rabbits for 4 weeks. Excretion study was carried out to determine whether oncolytic adenovirus was excreted from the beagle dogs after the single injection of carrier cells. Acute toxicity test did not show any lethal side effects in nude mice. In biodistribution test, single injection of carrier cells into ovarian tumor induced the peak levels of oncolytic adenovirus the next day but did not show any signifi cant levels of that in nude mice 14 days after injection. In chronic toxicity test, 8 injections of 1.25×10 7 cells/kg or less did not show any signifi cant toxicity in rabbits. In excretion test, oncolytic adenovirus was not excreted into the urine and the stool of beagle dogs. This oncolytic adenovirus-infected carrier cell system might prove effective and safe in the preclinical effi cacy and the biosafety test, respectively. Clinical trial is being scheduled to treat recurrent solid cancers.
Survivin-Targeting Artifi cial MicroRNAs Mediated by Adenovirus Devitalize Tumor Activity in Cancer Cells and Xenograft Models
Yudan Chi, 1 Xiang Wang, 1 Yong Yang, 1 Chao Zhang. 1 1 Anti-Infection Immunity and Vaccine Research, Institut Pasteur of Shanghai, Shanghai, China. As an inhibitor of apoptosis, survivin undertakes constitutively active in a variety of tumors for negatively regulation of cell cycle progressivity. It highly expresses in most human tumors and fetal tissue while being completely absent in terminally differentiated cells, which suggests survivin might be a target for cancer therapy that would distinguish transformed and normal cells. Here we demonstrate a promising therapeutic strategy against cancer via artifi cial microRNAs (amiRNAs) targeting survivin. After screening, two effective amiRNAs with the potential of suppressing survivin in cancer cells were obtained and then cloned into adenoviral vector. With dose-dependent recombinant viruses infecting cancer cells, downregulation of survivin in cancer cells could dramatically inhibit cancer cell growth and impair cell survival. Mechanistic investigations indicated survivin-targeting amiRNAs inducing cell apoptosis were associated with triggering the downstream effector caspase-3 and cleaved parp, and induction of P53 signaling pathway including the regulation of total P53 and phosphorylation level of P53. Furthermore, amiRNAs treatment contributed to the incomplete mitosis, corresponding to the cell cycle arrested at G2/M phase. Cancer cell
